Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SCNIBullishCorporate Developmentsnews

High materiality7/10

Scinai Immunotherapeutics secures CDMO deal and financing, extending runway to 2028

Oct 20, 2026, 8:54 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A meaningful CDMO win plus a liquidity-boosting financing improves cash flow visibility, reduces near-term dilution risk, and de-risks operating runway. History shows microcaps react positively when backlog rises and funding rounds are disclosed, provided execution remains on track.

AI summary

What happened, with direct paths to the underlying reporting

Scinai Immunotherapeutics announced a US CDMO agreement with $5.1M base fees and potential $5.85M later work, expanding backlog. Committed Customer Orders rose to about $8.1M as of Oct 20, 2026, up from $1.9M in 2025. Financing adds roughly $5.3M net, extending liquidity into late 2027 and potentially into 2028.

CDMO deal expands contracted work. It provides workload visibility.
Base fees about $5.1M; committed orders about $8.1M as of Oct 20, 2026.
Total opportunity exceeds $10M, including late-2027/2028 phases; uncommitted.
Financing boosts liquidity; runway extended to late 2027, possibly into 3Q2028.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Scinai Immunotherapeutics secures CDMO deal and financing, extending runway to 2028

Scinai Immunotherapeutics Secures $2.61 Million Financing for CDMO Expansion